Creative Bioarray Updates In Vitro Models for Drug Permeability Evaluation

Share this news:

Drug permeability is a key property to consider during the process of drug discovery, and Creative Bioarray has optimized a wide range of complementary in vitro models to help global scientists with their projects.

Recently, drug research and development has shown great prospects. During 2019, the US Food and Drug Administration (FDA) approved 48 new drugs, and the global drug discovery services market is projected to reach USD 19.1 billion by 2025.

Empowered by leading technology and years of experience in biomedical science, Creative Bioarray has established DDA (Drug Discovery Accelerator) platform with a team of experts with solid knowledge, aiming to offer a wide range of in vitro and in vivo services to help scientists at home and abroad accelerate their projects.

Since most drugs have to pass through at least one cellular membrane to reach the target cells, drug research development depends not only on high-throughput screening, but also on the in vitro model tests. Therefore, membrane permeability is a key property to consider during drug design, especially when dealing with small molecules with intracellular targets and drug permeability evaluation is one of the principal businesses of DDA platform. For example, intestinal permeability models, such as Caco-2 permeability models, MDCK permeability models and parallel artificial membrane permeability models, are all provided in a timely, effective manner.

As oral delivery is the most convenient form of pharmaceutical agents considering patient compliance, in vitro detection of intestinal permeability of new drugs can be implemented by Caco-2 permeability assay. Passive permeability, evaluation of MDR1 substrate, evaluation of BCRP substrate and inhibitor assessment in Caco-2 are all provided in Creative Bioarray with consistent, high quality Caco-2 assay data.

It is known that the passage into the brain is restricted by the blood-brain barrier (BBB). Thus, cell-based in vitro models are used to predict BBB permeability of new drugs in the early phase of drug development. Creative Bioarray offers MDCK permeability assay with the MDCK cell lines isolated from Cocker Spaniel kidney tubule, which is able to identify intestinal or CNS permeability and to investigate drug efflux to find out if the compound is suitable for oral administration or for use as a CNS therapeutic.

At present, high-throughput screening (HTS) for compounds with reasonable membrane permeability has become a pivotal goal in the early stages of dermal drug discovery and development process. Then, in vitro parallel artificial membrane permeability assay (PAMPA) is applied to use as one of the most interesting HTS tools. In Creative Bioarray, a full range of PAMPA models, including Original PAMPA, DOPC-PAMAPA, HDM-PAMPA, Bio-mimetic PAMPA and Double-SinkTM PAMPA, are all available in the fastest and most cost-effective way.

Apart from the aforementioned intestinal permeability models, Creative Bioarray also excels in ex vivo intestinal permeability models and blood-brain barrier permeability models. All absorption and permeability assays are available in standard human and animal model systems, and can be chosen individually, combined or as a selection of key services in candidate assessment packages. More information can be found on https://dda.creative-bioarray.com.

About Creative Bioarray
With more than 10 years of experience and in-house experts, Creative Bioarray is committed to helping global customers accelerate life science research, solve complex analytical challenges, and increase laboratory productivity. DDA platform of Creative Bioarray focuses on integrated drug discovery services to pharma, biotechnology companies, and academic institutions around the world.

Contact Info:
Name: Hannah Cole
Email: Send Email
Organization: Creative Bioarray
Website: https://www.creative-bioarray.com/

Release ID: 88948725

CONTACT ISSUER
Name: Hannah Cole
Email: Send Email
Organization: Creative Bioarray
SUBSCRIBE FOR MORE